ARS Pharmaceuticals, Inc. (SPRY) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts SPRY Hot Sheet
Join SI Premium – FREE
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q1 EPS of ($0.35), $0.01 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $7.97 million versus the consensus estimate of $7.48 million.
For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crude Inventory Fell 0.9 Million Barrels Last Week - EIA
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Netflix gains after Ackman endorsement and AI feature launch
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
